Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Jun 2021

Kamiyoshihara Mitsuhiro, Yazawa Tomohiro, Igai Hitoshi, Matsuura Natsumi, Ohsawa Fumi, Furusawa Shinya

Abstract excerpt

A 59-year-old man clinically diagnosed with primary lung cancer underwent left lower lobectomy and lymph node dissection( ND2a-2). The postoperative pathological stage was ⅠB(pT2aN0M0), and the lesion was positive for epidermal growth factor receptor(EGFR)exon 21 L858R mutation. Thirty months after surgery, the patient developed pleural dissemination and effusion in the left pleural cavity. Carboplatin(AUC=6, day...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Carcinoma, Adenosquamous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 34139736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].PMID 34139736Read ↗

Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report.Semantic proximity Read ↗

[Clinicopathologic Features and Prognostic Implications in 72 Cases with Lung Adenosquamous Carcinoma].Semantic proximity Read ↗

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.Semantic proximity Read ↗

Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.Semantic proximity Read ↗

[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].Semantic proximity Read ↗

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.Semantic proximity Read ↗

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.Semantic proximity Read ↗

[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].Semantic proximity Read ↗

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.Semantic proximity Read ↗

[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor].Semantic proximity Read ↗

Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.